Drug Profile
Trastuzumab monomethyl auristatin F - Iksuda Therapeutics/Shanghai Fosun Pharmaceutical
Alternative Names: FS-1502; IKS-014; LCB-14; LCB14-0110; Trastuzumab mafodotinLatest Information Update: 25 Oct 2023
Price :
$50
*
At a glance
- Originator LegoChem Biosciences
- Developer Iksuda Therapeutics; LegoChem Biosciences; Shanghai Fosun Pharmaceutical
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer; HER2 positive breast cancer
- Phase II Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Clinical Phase Unknown Oesophageal cancer; Urogenital cancer
Most Recent Events
- 23 Oct 2023 Phase-II clinical trials in Solid tumours in China (IV)
- 14 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (NCT05872295)
- 02 Jun 2023 Efficacy and adverse events data from a phase Ia/Ib trial in HER2 positive breast cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)